Shots:

• Ensoma to receive $100M in up front & preclinical research payment- $10M in equity investment- and is eligible to receive $1.25B as development and commercialization milestones along with royalties on sales of each product
• Takeda to get exclusive WW rights Ensoma’s Engenious vectors for up to five rare disease indications. Ensoma to conduct preclinical research activities for the Takeda programs- and both parties will share in responsibilities leading to the submission of IND applications. Takeda will lead development activities thereafter
• Additionally- Ensoma launches to next-generation in vivo approach to deliver first “off-the-shelf” genomic medicines with the $70M Series A funding

 ­ Ref: Businesswire | Image: Businesswire